CCI
GEVA

Columbus Circle Investors’s SYNAGEVA BIOPHARMA CORP COM STK (DE) GEVA Stock Holding History

Columbus Circle Investors’s Portfolio GEVA Stock Details GEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-261,590
Closed -$27.4M – 322
2014
Q2 		$27.4M Buy
261,590
+75,286
+40% +$6.4M 0.19% 123
2014
Q1 		$15.5M Buy
+186,304
New +$17.2M 0.1% 186

Other funds holding GEVA

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
CWAM
Columbia Wanger Asset Management Chicago, Illinois $6.69B AUM 31.14% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return

Columbus Circle Investors's GEVA Position: Q3 2014 in Review

Columbus Circle Investors sold out of SYNAGEVA BIOPHARMA CORP COM STK (DE) (GEVA) in Q3 2014, closing a stake of 261,590 shares — an estimated $27.4M sold.

Columbus Circle Investors first reported a position in GEVA in Q1 2014 and held it in 2 quarters. The position peaked at $27.4M in Q2 2014. 120 funds tracked by Wall St. Rank hold GEVA as of Q3 2014.

  • Columbus Circle Investors reported no remaining SYNAGEVA BIOPHARMA CORP COM STK (DE) position as of Q3 2014 after selling out during the quarter.
  • Columbus Circle Investors sold 261,590 SYNAGEVA BIOPHARMA CORP COM STK (DE) shares in Q3 2014, an estimated $27.4M.
  • Columbus Circle Investors first reported a position in SYNAGEVA BIOPHARMA CORP COM STK (DE) in Q1 2014 and held it in 2 quarters.
  • Columbus Circle Investors's SYNAGEVA BIOPHARMA CORP COM STK (DE) position peaked at $27.4M in Q2 2014.
  • 120 funds tracked by Wall St. Rank held SYNAGEVA BIOPHARMA CORP COM STK (DE) as of Q3 2014.

Based on Columbus Circle Investors's 13F filing for Q3 2014, filed 5 Nov 2014.